Korea United Pharm

At a glance

Korea United Pharm filed 62 disclosures in the last 12 months, including 8 insider, 7 5% holder, 3 earnings and 3 buyback. The most recent key filing was on Oct 30: Operating profit ₩2.8B, down 77.4% YoY. Revenue ₩68.1B, down 8.5% YoY.

Revenue for 2025 was ₩289B, up 0% on 2024. Operating margin was 17.2% against 19.5% a year earlier. Debt was 14% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩151B and operating profit of ₩24.6B.

The 2025 annual report lists 902 employees with an average tenure of 7.3 years and average pay of ₩67M, #693 of 1,829 listed companies by average pay. Its 8 directors and auditors were paid ₩531M each on average. It paid ₩610 per common share in cash dividends, against ₩450 a year earlier (+35.6%). 강덕영 and related parties held 40.72% at year end.

From the 2025 annual report

Staff: 902 (627 men, 275 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩60.2B. Directors and auditors: 8, paid ₩4.3B in total.

Dividends (common shares)

Largest shareholder

강덕영 holds 15.21%; with 17 related parties the group holds 40.72% of common shares at year end (from 37.54% at the start of the year).

Individuals paid ₩500M or more

Auditor: 선진회계법인 · opinion: Unqualified.

Rankings: Low debt #68 of 1,372

Source: 2025 annual business report (DART). How figures are combined

Financial summary